<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26901">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117115</url>
  </required_header>
  <id_info>
    <org_study_id>201404063</org_study_id>
    <nct_id>NCT02117115</nct_id>
  </id_info>
  <brief_title>Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>GVHD</acronym>
  <official_title>Early Post-transplant Contrast-enhanced Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell
      transplant, and radiographic evidence of mucosal inflammation will be correlated with the
      subsequent development of acute graft versus host disease.  The primary endpoint is the
      feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant
      period, as defined by the risk of contrast-related nephropathy or allergic reaction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Abdominal CT risk of contrast related nephropathy or allergic reaction</measure>
    <time_frame>180 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between CT risk scores and occurrence of acute GVHD</measure>
    <time_frame>180 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>2 x 2 chi-squared test (CT score 0-1 vs. 2-3 and presence vs. absence of acute GVHD)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Myelogenous, Chronic</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CT scan with contrast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>CT scan performed between Day +7 and Day +14.</description>
    <arm_group_label>CT scan with contrast</arm_group_label>
    <other_name>CT scan with contrast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven diagnosis of a hematologic malignancy

          -  Scheduled to undergo allogeneic SCT from a matched sibling donor or an unrelated
             donor who is 10/10 or 9/10 HLA match. Transplant eligibility is per standard and
             institutional criteria.

          -  Age 18-60 years

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Documented or reported contrast allergy

          -  Estimated glomerular filtration rate (GFR) &lt; 60

          -  Deemed too sick by clinician to leave the floor for imaging

          -  &quot;Nothing-per-mouth&quot; status for other clinical reasons

        Inclusion of Women and Minorities

        -Both men and women and members of all races and ethnic groups are eligible for this
        trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Cashen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Cashen, M.D.</last_name>
    <phone>314-454-8491</phone>
    <email>acashen@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Cashen, M.D.</last_name>
      <phone>314-454-8491</phone>
      <email>acashen@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Armin Rashidi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micheal Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
